Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.51 USD
Change Today -0.22 / -12.72%
Volume 2.9M
VVUS On Other Exchanges
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

vivus inc (VVUS) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/1/14 - $4.89
52 Week Low
07/31/15 - $1.28
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for VIVUS INC (VVUS)

vivus inc (VVUS) Related Businessweek News

View More BusinessWeek News

vivus inc (VVUS) Details

VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension. The company has development, license and clinical trial, and commercial supply agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. It also has license and commercialization agreements with Berlin-Chemie AG and Auxilium Pharmaceuticals, Inc. to commercialize and promote SPEDRA; and with Sanofi Winthrop Industrie to commercialize and promote avanafil. VIVUS, Inc. was founded in 1991 and is headquartered in Mountain View, California.

94 Employees
Last Reported Date: 02/25/15
Founded in 1991

vivus inc (VVUS) Top Compensated Officers

Chief Executive Officer, Chief Commercial Off...
Total Annual Compensation: $650.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $350.0K
Senior Vice President of Business Development...
Total Annual Compensation: $425.0K
Vice President of Clinical Development
Total Annual Compensation: $432.3K
Vice President of Medical & Regulatory Affair...
Total Annual Compensation: $385.0K
Compensation as of Fiscal Year 2014.

vivus inc (VVUS) Key Developments

VIVUS Inc. to Report Q2, 2015 Results on Jul 30, 2015

VIVUS Inc. announced that they will report Q2, 2015 results at 4:30 PM, US Eastern Standard Time on Jul 30, 2015

VIVUS Inc., Q2 2015 Earnings Call, Jul 30, 2015

VIVUS Inc., Q2 2015 Earnings Call, Jul 30, 2015

VIVUS Inc. Enters in to Letter Agreement with Wesley W. Day

On July 20, 2015, VIVUS Inc. entered into a letter agreement regarding retention benefits, or the Letter Agreement, with Wesley W. Day, Ph.D. Under the Letter Agreement and subject to certain conditions, including the execution of a separation and release of claims agreement, if Dr. Day (i) remains an employee of the company from the date of the Letter Agreement through December 31, 2015 or (ii) prior to December 31, 2015, Dr. Day's employment with the company is terminated for any reason other than due to cause and such termination is not as a result of his death or disability, then Dr. Day will receive the following: (i) a lump sum cash payment in an amount equal to $616,000 (which is equal to one year of his base salary and one year of his target bonus); (ii) a lump sum cash bonus for calendar year 2015 that will be a minimum of $119,150 and a maximum of $149,600 based upon the achievement of certain milestones; and (iii) up to 12 months of reimbursement for premiums paid for COBRA coverage (or a taxable lump sum payment in an amount equal to the monthly premiums paid for COBRA in the event the company cannot provide reimbursement benefits without potentially violating applicable laws). In addition, under the Letter Agreement, the company and Dr. Day agreed that his employment will terminate on December 31, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VVUS:US $1.51 USD -0.22

VVUS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $4.04 USD +0.07
GlaxoSmithKline Consumer Healthcare Ltd 6,294 INR 0.00
Novo Nordisk A/S kr398.40 DKK +1.20
Orexigen Therapeutics Inc $4.00 USD +0.05
Takeda Pharmaceutical Co Ltd ¥6,240 JPY +138.00
View Industry Companies

Industry Analysis


Industry Average

Valuation VVUS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.6x
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VIVUS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at